The use of social media, including Facebook, Twitter, and newer patient specific platforms, is evolving and impacting clinical research. Millennials, who are becoming an important demographic to the pharmaceutical industry, are responsive to outreach via social media. The use of social media may reduce barriers to entry into clinical trials. Recruiting efforts with patient friendly engagement on the internet can be more effective than traditional local advertising. Increased communication between the sponsor and patient may aid in retention, and patients benefit from forums that offer support and education. However, patients' ability to interact with each other and discuss adverse events may also lead to unintended negative consequences. Misinformation about the trial or drug may be perpetuated through social media, possibly compromising the adverse event reporting. Trial sponsors across the industry have not enacted consistent social media policies. This presentation will propose strategies to harness the positive aspects of social media on clinical trials while minimizing the negative.